Miragliotta G, Marcuccio C, Ricci G, Barone G, Fumarola D
J Leukoc Biol. 1985 Jan;37(1):101-8. doi: 10.1002/jlb.37.1.101.
Thromboembolic complications are known in cancer patients after i.v. administration of Corynebacterium parvum. We examined the ability of this organism to induce production of procoagulant activity by human blood mononuclear leukocytes in vitro. After 4 hours incubation Corynebacterium parvum was an effective stimulant for mononuclear leukocytes, behaving in the same way as the typical gram-negative bacterium Escherichia coli, whereas mononuclear cells incubated with Staphylococcus aureus were not affected. Corynebacterium parvum used was found devoid of endotoxin by the Limulus assay and was not affected by Polymyxin B, which, on the contrary, inhibited Escherichia coli-induced production of procoagulant activity. Intact Corynebacterium parvum may be required for the production of procoagulant activity and, although this specific aspect of the research will require further study, from the exposed data it is concluded that such a production could be a factor contributing to the pathogenesis of the coagulopathy following Corynebacterium parvum therapy.
静脉注射短小棒状杆菌后,癌症患者会出现血栓栓塞并发症。我们检测了这种微生物在体外诱导人血单核白细胞产生促凝活性的能力。孵育4小时后,短小棒状杆菌是单核白细胞的有效刺激物,其作用方式与典型的革兰氏阴性菌大肠杆菌相同,而与金黄色葡萄球菌一起孵育的单核细胞则未受影响。所使用的短小棒状杆菌经鲎试剂检测未发现内毒素,且不受多粘菌素B的影响,相反,多粘菌素B可抑制大肠杆菌诱导的促凝活性产生。产生促凝活性可能需要完整的短小棒状杆菌,尽管该研究的这一特定方面还需要进一步研究,但从已公开的数据可以得出结论,这种产生可能是导致短小棒状杆菌治疗后凝血病发病机制的一个因素。